| 1 |
35463361 | Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1- Mediated Gemcitabine Chemoresistance. | 2022 |
4 |
| 2 |
34347777 | Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer. | 2021 |
3 |
| 3 |
31177402 | The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid. | 2020 Jun |
3 |
| 4 |
33147005 | Reversing P-Glycoprotein-Associated Multidrug Resistance of Breast Cancer by Targeted Acid-Cleavable Polysaccharide Nanoparticles with Lapatinib Sensitization. | 2020 Nov 18 |
1 |
| 5 |
31262905 | Tyrosine Kinase Inhibitors Imatinib and Erlotinib Increase Apoptosis of Antimitotic Drug-resistant KBV20C Cells Without Inhibiting P-gp. | 2019 Jul |
4 |
| 6 |
28596528 | Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter. | 2017 Jun 8 |
2 |
| 7 |
26036634 | Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes. | 2015 Jul 10 |
2 |
| 8 |
26054673 | Lapatinib enhances the cytotoxic effects of doxorubicin in MCF-7 tumorspheres by inhibiting the drug efflux function of ABC transporters. | 2015 May |
1 |
| 9 |
27137717 | Effect of lapatinib on oral digoxin absorption in patients. | 2015 Nov |
4 |
| 10 |
25105301 | Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport function. | 2014 Sep 8 |
1 |
| 11 |
22389470 | HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer. | 2012 Apr |
1 |
| 12 |
22414725 | GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance. | 2012 Jun 15 |
5 |
| 13 |
20607587 | Modulation of P-gp expression by lapatinib. | 2011 Dec |
5 |
| 14 |
21514634 | Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. | 2011 Jul |
2 |
| 15 |
19720054 | Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. | 2010 Jan 15 |
3 |
| 16 |
19854117 | Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib. | 2009 Dec 1 |
2 |
| 17 |
18216274 | The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. | 2008 Apr |
4 |
| 18 |
18829547 | Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. | 2008 Oct 1 |
11 |